Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients?

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/four-new-glaucoma-developments-from-the-last-two-weeks-which-one-could-matter-most-for-patientsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients? Between August 21 and September 4, 2026, four glaucoma developments attracted attention: G01 / rhNGF-V2 neuroprotective eye drops Acid sphingomyelinase and ceramide metabolism as retinal ganglion-cell targets Optical coherence tomography angiography for earlier progression detection NCX 470, now called K-911, approaching United States regulatory review They are not equally important. One is already available as a diagnostic technology. One is close to possible approval but appears to be an incremental pressure-lowering improvement. The other two could eventually change the biology of glaucoma, but both remain uncertain and relatively early. This assessment uses information available through September 4, 2026, with the current regulatory status checked through September 11, 2026. > Important: The probabilities below are informed estimates, not clinical-trial results or regulatory predictions. “Changing care” means becoming sufficiently useful that it changes routine glaucoma management within approximately the next 5–10 years. At-a-Glance Comparison For the full table, please open this article on visualfieldtest.com. The Short Answer Most likely to help patients in the next 5–10 years NCX 470 / K-911 is the most likely to produce a measurable patient benefit because it has already completed large Phase 3 trials and has entered regulatory review. Most likely to improve glaucoma monitoring Optical coherence tomography angiography is the most immediately useful development. It may identify progression roughly two years before visual-field progression in some patients, although it is not perfect and does not directly treat glaucoma. () Highest upside G01 / rhNGF-V2 has the greatest potential upside because it aims to protect retinal ganglion cells independently of intraocular pressure. However, its current evidence is much weaker than the evidence supporting NCX 470. Most interesting biological discovery The acid sphingomyelinase–ceramide pathway may reveal a new way to protect retinal ganglion cells, but it is still a target rather than a treatment. --- G01 / rhNGF-V2 Neuroprotective Eye Drops What was reported? G01 is an investigational eye drop being developed in China for optic nerve injury associated with open-angle glaucoma. A Phase 2 study was updated on August 24, 2026, after being first posted on August 20, just outside the requested date range. The randomized, double-masked study plans to enroll approximately 90 patients with progressing primary open-angle glaucoma. It compares G01 concentrations of 100 micrograms per milliliter and 200 micrograms per milliliter with placebo. The study’s primary outcome is change in visual-field mean deviation after approximately 24 weeks of treatment, with additional structural, electrophysiological, pharmacokinetic, and immunogenicity measurements. Completion is estimated for late 2027. () A separate Phase 1 study in healthy volunteers is testing single and repeated doses of 100, 200, and 400 micrograms per milliliter. No public clinical efficacy results were available by September 4, 2026. () What is rhNGF-V2 supposed to do? Nerve growth factor is a neurotrophic protein involved in neuronal survival and repair. The goal is not to lower eye pressure but to make retinal ganglion cells more resistant to injury. Public company information identifies G01’s active ingredient as recombinant human nerve growth factor variant 2. A related patent describes a modified nerve growth factor known as K34D, which appears to be the likely molecular identity of rhNGF-V2, although the exact identity and characteristics of the clinical product have not been independently confirmed in a peer-reviewed clinical publication. This is therefore a strong inference, not a fully established fact. () The proposed advantage of the modified molecule is greater signaling through the protective tropomyosin receptor kinase A pathway with less potentially harmful signaling through the p75 neurotrophin receptor. The patent reports substantially reduced binding to the p75 receptor for K34D and even more receptor selectivity for a related double-mutant molecule. () Strength of the evidence Known facts G01 is in a registered Phase 2 glaucoma trial. No G01 efficacy results have been publicly reported. A separate healthy-volunteer safety and pharmacokinetic study is also registered. A patent reports protective effects for K34D in rat ocular-hypertension models. Earlier human research with conventional recombinant human nerve growth factor established short-term safety but did not demonstrate statistically significant neuroenhancement. Animal evidence In a patent-described rat model of chronic ocular hypertension, treatment began after pressure elevation had already occurred. K34D eye drops did not lower intraocular pressure, but they were associated with: Less retinal ganglion-cell loss Less optic-nerve axon damage Better pattern electroretinogram responses In one experiment, retinal ganglion-cell loss was approximately 59% in vehicle-treated animals versus 31% with K34D, a roughly 50% relative reduction in cell loss. However, the groups were small, the work was reported in a patent rather than an independent peer-reviewed paper, and the findings have not yet been replicated publicly by unrelated laboratories. () Human evidence for the nerve growth factor class A Phase 1b randomized trial gave conventional recombinant human nerve growth factor to 40 patients and vehicle to 20 patients for eight weeks. It found: No treatment-related serious adverse events No meaningful intraocular-pressure effect No statistically significant short-term improvement in visual fields or optical coherence tomography Ocular pain in approximately half of the nerve-growth-factor group Irritation, photophobia, and other surface symptoms in some patients The researchers noted that the trial was too short and too small to test true neuroprotection. Still, the absence of a clear short-term functional signal is important. It means that the modified G01 molecule must prove that it is meaningfully better than conventional nerve growth factor, not merely safer or more selective. () Biological plausibility The biological rationale is strong enough to justify clinical testing: Retinal ganglion cells depend on neurotrophic support. Glaucoma involves axonal injury, impaired transport, metabolic stress, and eventual cell death. Neurotrophic signaling could theoretically preserve stressed but living retinal ganglion cells. The patent data suggest a possible advantage from modifying receptor selectivity. The main biological problem is delivery. A topical eye drop must reach the retina and optic nerve in an adequate concentration. The cornea, anterior chamber, lens, vitreous, and retinal barriers make posterior-segment delivery difficult. A large dose may be needed, which could worsen surface pain or irritation. Potential magnitude of benefit Maximum plausible benefit If the animal findings translate unusually well to humans, G01 could: Slow retinal ganglion-cell death by a substantial amount Delay visual-field progression Provide benefit even when intraocular pressure is already at target Possibly improve function in retinal ganglion cells that are impaired but not yet dead Most realistic benefit The more realistic initial outcome would be a modest slowing of progression, perhaps in a subgroup of patients with active disease despite acceptable intraocular pressure. A benefit of approximately 10–25% slower functional deterioration would be clinically useful but would not constitute a cure. The possibility of a 30–50% reduction in progression is biologically conceivable but currently speculative. Risks The major known concern is tolerability. Conventional nerve growth factor produced substantial ocular pain and irritation in the Phase 1b trial. A modified molecule may have a better profile, but this has not yet been demonstrated in patients. Other concerns include: Ocular surface inflammation Photophobia and discomfort Immunogenicity against a repeated protein treatment Insufficient retinal exposure Possible unintended effects on sensory nerves or inflammatory signaling The need for multiple daily doses Likely patient population The most likely initial target would be patients with: Progressing open-angle glaucoma Intraocular pressure already reasonably controlled Mild-to-moderate disease with surviving retinal ganglion cells Documented structural or visual-field progression Patients with advanced glaucoma could benefit from preservation of remaining vision, but a treatment cannot rescue retinal ganglion cells that have already died. Does it work independently of intraocular pressure? Probably yes. The patent experiments reported no intraocular-pressure lowering, yet showed retinal ganglion-cell and axon protection. The current Phase 2 trial also appears designed for patients with relatively controlled pressure, strengthening the idea that G01 is intended as an adjunctive, pressure-independent treatment. () Could it preserve or restore vision? Preserve vision: Potentially yes. Restore lost function:Support the show